Nothing Special   »   [go: up one dir, main page]

SG11202106520VA - Kif18a inhibitors - Google Patents

Kif18a inhibitors

Info

Publication number
SG11202106520VA
SG11202106520VA SG11202106520VA SG11202106520VA SG11202106520VA SG 11202106520V A SG11202106520V A SG 11202106520VA SG 11202106520V A SG11202106520V A SG 11202106520VA SG 11202106520V A SG11202106520V A SG 11202106520VA SG 11202106520V A SG11202106520V A SG 11202106520VA
Authority
SG
Singapore
Prior art keywords
kif18a
inhibitors
kif18a inhibitors
Prior art date
Application number
SG11202106520VA
Other languages
English (en)
Inventor
Nuria A Tamayo
Abhisek Banerjee
James Alexander Brown
Michael J Frohn
Jian Jeffrey Chen
Kexue Li
Qingyian Liu
Jonathan Dante Low
Vu Ma
Liping H Pettus
Mary Catherine Walton
Ana Elena Minatti
Matthew Paul Bourbeau
Lei Jia
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202106520VA publication Critical patent/SG11202106520VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202106520VA 2018-12-20 2019-12-20 Kif18a inhibitors SG11202106520VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862783061P 2018-12-20 2018-12-20
PCT/US2019/068169 WO2020132648A1 (fr) 2018-12-20 2019-12-20 Inhibiteurs de kif18a

Publications (1)

Publication Number Publication Date
SG11202106520VA true SG11202106520VA (en) 2021-07-29

Family

ID=69187977

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106520VA SG11202106520VA (en) 2018-12-20 2019-12-20 Kif18a inhibitors

Country Status (23)

Country Link
US (3) US11236069B2 (fr)
EP (1) EP3897852A1 (fr)
JP (1) JP7407196B2 (fr)
KR (1) KR20210106474A (fr)
CN (1) CN113226473A (fr)
AR (1) AR117490A1 (fr)
AU (1) AU2019403486A1 (fr)
BR (1) BR112021011989A2 (fr)
CA (1) CA3123871A1 (fr)
CL (1) CL2021001634A1 (fr)
CO (1) CO2021008224A2 (fr)
CR (1) CR20210387A (fr)
EA (1) EA202191730A1 (fr)
IL (1) IL283639B2 (fr)
JO (1) JOP20210154B1 (fr)
MA (1) MA54543A (fr)
MX (1) MX2021007156A (fr)
PE (1) PE20211475A1 (fr)
SA (1) SA521422303B1 (fr)
SG (1) SG11202106520VA (fr)
TW (1) TWI844602B (fr)
UY (1) UY38526A (fr)
WO (1) WO2020132648A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc KIF18A inhibitors
JP2022513967A (ja) * 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
JP2023521802A (ja) * 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤
MX2023004802A (es) 2020-10-27 2023-06-22 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso.
CN117651700A (zh) 2021-04-29 2024-03-05 安进公司 2-氨基苯并噻唑化合物及使用方法
WO2022268230A1 (fr) 2021-06-25 2022-12-29 杭州英创医药科技有限公司 Composé destiné à être utilisé en tant qu'inhibiteur de kif18a
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
CN118215657A (zh) 2021-11-19 2024-06-18 微境生物医药科技(上海)有限公司 Kif18a抑制剂
AR128353A1 (es) * 2022-01-26 2024-04-24 Amgen Inc Síntesis de un inhibidor de kif18a
AU2023221732A1 (en) 2022-02-16 2024-08-15 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023159086A1 (fr) 2022-02-16 2023-08-24 Amgen Inc. Composés de quinazoline et leur utilisation en tant qu'inhibiteurs de protéines kras mutantes
WO2023174175A1 (fr) * 2022-03-17 2023-09-21 微境生物医药科技(上海)有限公司 Inhibiteur de kif18a
AU2023254325A1 (en) * 2022-04-15 2024-10-17 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Kif18a inhibitor and use thereof
CN116554151B (zh) * 2022-05-13 2024-09-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
TW202400582A (zh) * 2022-05-13 2024-01-01 大陸商上海湃隆生物科技有限公司 驅動蛋白kif18a抑制劑及其應用
WO2024002328A1 (fr) * 2022-06-30 2024-01-04 勤浩医药（苏州）有限公司 Composé contenant de l'azote et son utilisation
WO2024032661A1 (fr) * 2022-08-11 2024-02-15 山东轩竹医药科技有限公司 Inhibiteur de kif18a et son utilisation
WO2024035950A1 (fr) * 2022-08-12 2024-02-15 Accent Therapeutics, Inc. Inhibiteurs de kif18a et leurs utilisations
WO2024039829A1 (fr) * 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibiteurs de kif18a et leurs utilisations
TW202413334A (zh) * 2022-09-08 2024-04-01 大陸商長春金賽藥業有限責任公司 Ｋｉｆ１８ａ抑制劑化合物、藥物組合物及其製備方法和用途
WO2024051812A1 (fr) * 2022-09-09 2024-03-14 先声再明医药有限公司 Composé amide, composition et utilisation correspondante
TW202415648A (zh) * 2022-09-30 2024-04-16 大陸商長春金賽藥業有限責任公司 稠環類kif18a抑制劑化合物、藥物組合物及其製備方法和用途
WO2024067465A1 (fr) * 2022-09-30 2024-04-04 山东轩竹医药科技有限公司 Inhibiteur de kif18a
CN117917405A (zh) * 2022-10-21 2024-04-23 杭州邦顺制药有限公司 Kif18a蛋白抑制剂
WO2024109923A1 (fr) * 2022-11-24 2024-05-30 InventisBio Co., Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs utilisations
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂
WO2024114730A1 (fr) * 2022-11-30 2024-06-06 微境生物医药科技(上海)有限公司 Composition pharmaceutique pour le traitement du cancer
TW202430166A (zh) * 2022-12-02 2024-08-01 大陸商深圳眾格生物科技有限公司 醯胺或脲類化合物
WO2024125488A1 (fr) * 2022-12-14 2024-06-20 浙江海正药业股份有限公司 Dérivé d'amide aromatique, son procédé de préparation et son utilisation pharmaceutique
WO2024125626A1 (fr) * 2022-12-16 2024-06-20 Nuphase Therapeutics (Hangzhou) Limited., Co. Composé azoté, composition pharmaceutique et utilisation associée
WO2024137984A1 (fr) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibiteurs de kif18a et utilisations associées
WO2024140799A1 (fr) * 2022-12-28 2024-07-04 Insilico Medicine Ip Limited Inhibiteurs de kif18a et utilisations associées
WO2024146593A1 (fr) * 2023-01-05 2024-07-11 浙江海正药业股份有限公司 Dérivé d'amide aromatique, son procédé de préparation et son utilisation médicale
WO2024153217A1 (fr) * 2023-01-20 2024-07-25 Insilico Medicine Ip Limited Inhibiteurs de kif18a et leurs utilisations
CN118598855A (zh) * 2023-03-06 2024-09-06 武汉人福创新药物研发中心有限公司 抑制kif18a的化合物及其用途
CN115947717B (zh) * 2023-03-09 2023-05-30 英矽智能科技(上海)有限公司 一类kif18a抑制剂
WO2024217348A1 (fr) * 2023-04-18 2024-10-24 南京同诺康医药科技有限公司 Inhibiteur de kif18a, son procédé de préparation et son utilisation
CN116535400B (zh) * 2023-04-26 2024-08-16 上海湃隆生物科技有限公司 氮杂螺环化合物及其应用

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
NZ258697A (en) 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
CA2148931A1 (fr) 1993-10-01 1995-04-13 Jurg Zimmermann Derives pyrimidineamine et leurs procedes de preparation
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995024190A2 (fr) 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
EP0756627A1 (fr) 1994-04-15 1997-02-05 Amgen Inc. Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996030347A1 (fr) 1995-03-30 1996-10-03 Pfizer Inc. Derives de quinazoline
NZ304859A (en) 1995-04-03 2000-01-28 Novartis Ag 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
DE69624921T2 (de) 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
WO1997002266A1 (fr) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
JP4275733B2 (ja) 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジンおよびその製造法
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE244719T1 (de) 1996-03-15 2003-07-15 Novartis Pharma Gmbh N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
WO1997038983A1 (fr) 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
JP2000512990A (ja) 1996-06-24 2000-10-03 ファイザー・インク 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912572B1 (fr) 1996-07-13 2003-01-15 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
EA199900036A1 (ru) 1996-07-18 1999-06-24 Пфайзер Инк Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4242928B2 (ja) 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト 置換ピロロピリミジンおよびその製造方法
BR9711223A (pt) 1996-08-23 1999-08-17 Pfizer Derivados de cido arilsulfonilamino-hidrox mico
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
JP4205168B2 (ja) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
AU722784B2 (en) 1997-02-11 2000-08-10 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
AU8689298A (en) 1997-08-05 1999-03-01 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
DE69822839T2 (de) 1997-08-08 2004-08-19 Pfizer Products Inc., Groton Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
WO1999040196A1 (fr) 1998-02-09 1999-08-12 Genentech, Inc. Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
AU756838B2 (en) 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU747427B2 (en) 1998-07-10 2002-05-16 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2341409A1 (fr) 1998-08-31 2000-03-09 Merck And Co., Inc. Nouveaux inhibiteurs d'angiogenese
PT1004578E (pt) 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
PT1196186E (pt) 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
WO2001014387A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
EP1244647B1 (fr) 1999-11-05 2006-06-21 AstraZeneca AB Derives de quinazoline utilises en tant qu'inhibiteurs du facteur de croissance endotheliale vasculaire (vegf)
ES2367007T3 (es) 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2400040A1 (fr) 2000-02-25 2001-08-30 Immunex Corporation Antagonistes des integrines
US6651123B1 (en) 2000-03-30 2003-11-18 International Business Machines Corporation File system locking
US6534309B1 (en) 2000-08-03 2003-03-18 Cytokinetics, Inc. Motor proteins and methods for their use
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
EP1343782B1 (fr) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Composes chimiques
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2003299517A1 (en) 2002-05-23 2004-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP2305813A3 (fr) 2002-11-14 2012-03-28 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
US7423018B2 (en) 2002-12-13 2008-09-09 University Of Massachusetts Kinesin-like proteins and methods of use
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
US20060173033A1 (en) 2003-07-08 2006-08-03 Michaela Kneissel Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1660126A1 (fr) 2003-07-11 2006-05-31 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
WO2005016252A2 (fr) 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Macrocycles contenant du phosphore
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
AU2004264533B2 (en) 2003-08-15 2009-01-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1692318A4 (fr) 2003-12-02 2008-04-02 Genzyme Corp Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
BRPI0417498A (pt) 2003-12-09 2007-05-29 Us Gov Health & Human Serv método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
WO2006083289A2 (fr) 2004-06-04 2006-08-10 Duke University Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CA2576619A1 (fr) 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines destinees a etre utilisees en tant qu'inhibiteurs de la kinesine eg5
KR100859891B1 (ko) 2004-08-26 2008-09-23 화이자 인코포레이티드 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
CA2582163A1 (fr) 2004-10-13 2006-04-27 Wyeth Analogues de la 17-hydroxywortmannine employes en tant qu'inhibiteurs de pi3k
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
WO2006114788A1 (fr) 2005-04-25 2006-11-02 Ramot At Tel Aviv University Ltd. Polypeptides de kinesine, polynucleotides codant pour ceux-ci et compositions et leurs methodes d'utilisation
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090012085A1 (en) 2005-09-20 2009-01-08 Charles Michael Baum Dosage forms and methods of treatment using a tyrosine kinase inhibitor
JP2009514866A (ja) 2005-11-02 2009-04-09 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
WO2007133822A1 (fr) 2006-01-19 2007-11-22 Genzyme Corporation Anticorps anti-gitr destinés au traitement du cancer
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
AR062200A1 (es) 2006-08-04 2008-10-22 Aeterna Zentaris Gmbh Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
TWI499420B (zh) 2006-12-07 2015-09-11 Hoffmann La Roche 肌醇磷脂３-激酶抑制劑化合物及使用方法
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
WO2010003118A1 (fr) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Protéines de liaison multi-cibles antagonistes du tgf-b
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
DK3023438T3 (en) 2009-09-03 2020-05-11 Merck Sharp & Dohme Anti-gitr-antistoffer
EP2295543A1 (fr) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé de préparation de virus de la grippe
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EA023674B1 (ru) 2009-12-29 2016-06-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Гетеродимерные связывающие белки и их применение
WO2011085261A1 (fr) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Inhibiteurs de hedgehog
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
ES2672992T3 (es) 2013-08-09 2018-06-19 Takeda Pharmaceutical Company Limited Compuesto aromático
US20170095479A1 (en) 2014-05-29 2017-04-06 Merck Sharp & Dohme Corp. Methods for Treating Cancer with a WEE1 Inhibitor
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
SG11201808167VA (en) 2016-03-24 2018-10-30 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN108768023B (zh) 2018-08-13 2020-01-07 珠海格力电器股份有限公司 转子组件及交替极电机
DE102018213662A1 (de) 2018-08-14 2020-02-20 Robert Bosch Gmbh Lautsprecher mit einem darin enthaltenen Leuchtelement
CN109039072B (zh) 2018-08-21 2020-09-08 南京南瑞继保电气有限公司 一种双极双向直流变换器及其控制方法和控制装置
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc KIF18A inhibitors
JP2022513967A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
CA3123044A1 (fr) 2018-12-20 2020-06-25 Amgen Inc. Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a
GB2617512B (en) 2019-04-05 2023-12-27 Earli Inc Improved methods and compositions for synthetic biomarkers
WO2020226333A1 (fr) 2019-05-03 2020-11-12 주식회사 디시젠 Méthode de prédiction et de pronostic du cancer et composition à cet effet
WO2021011634A1 (fr) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation de protéines et leurs utilisations
EP4007756A1 (fr) 2019-08-02 2022-06-08 Amgen Inc. Inhibiteurs de kif18a
CN114391012A (zh) 2019-08-02 2022-04-22 美国安进公司 作为kif18a抑制剂的吡啶衍生物
EP4007753A1 (fr) 2019-08-02 2022-06-08 Amgen Inc. Inhibiteurs de kif18a
JP2022542967A (ja) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
WO2021161323A1 (fr) 2020-02-16 2021-08-19 Genetikaplus Ltd. Procédés de pronostic thérapeutique
US12187992B2 (en) 2020-02-19 2025-01-07 The Regents Of The University Of California Method and device for early cancer screening
JP2023521802A (ja) 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤
WO2021231413A1 (fr) 2020-05-11 2021-11-18 University Of Vermont Approche de traitement impliquant l'inhibition de kif18a pour des tumeurs instables du point de vue chromosomique
MX2023004802A (es) 2020-10-27 2023-06-22 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso.
US20240261425A1 (en) 2021-04-09 2024-08-08 Nanjing University Conjugate and the preparing method and use thereof
WO2022268230A1 (fr) 2021-06-25 2022-12-29 杭州英创医药科技有限公司 Composé destiné à être utilisé en tant qu'inhibiteur de kif18a
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
WO2023041055A1 (fr) 2021-09-16 2023-03-23 微境生物医药科技(上海)有限公司 Inhibiteur de kif18a
CN118201923A (zh) 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
CN118215657A (zh) 2021-11-19 2024-06-18 微境生物医药科技(上海)有限公司 Kif18a抑制剂
WO2023146979A1 (fr) 2022-01-27 2023-08-03 The Board Of Trustees Of The Leland Stanford Junior University Plateforme de cytométrie de masse à cellule unique pour cartographier les effets d'agents candidats sur le cartilage
AU2023254325A1 (en) 2022-04-15 2024-10-17 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Kif18a inhibitor and use thereof
TW202346288A (zh) 2022-04-28 2023-12-01 美商佛拉斯托醫療公司 用於抑制ｋｉｆ１８ａ之化合物
WO2023212714A1 (fr) 2022-04-29 2023-11-02 Amgen Inc. Inhibition de kif18a pour le traitement du cancer

Also Published As

Publication number Publication date
SA521422303B1 (ar) 2023-12-11
MA54543A (fr) 2022-03-30
CA3123871A1 (fr) 2020-06-25
EA202191730A1 (ru) 2021-08-24
TW202034924A (zh) 2020-10-01
MX2021007156A (es) 2021-08-16
US20240317715A1 (en) 2024-09-26
JOP20210154B1 (ar) 2023-09-17
CR20210387A (es) 2021-08-19
KR20210106474A (ko) 2021-08-30
US20200239441A1 (en) 2020-07-30
PE20211475A1 (es) 2021-08-05
AR117490A1 (es) 2021-08-11
US11236069B2 (en) 2022-02-01
US12054476B2 (en) 2024-08-06
CL2021001634A1 (es) 2021-12-10
EP3897852A1 (fr) 2021-10-27
IL283639A (en) 2021-07-29
JP2022513972A (ja) 2022-02-09
AU2019403486A1 (en) 2021-06-24
BR112021011989A2 (pt) 2021-09-08
JP7407196B2 (ja) 2023-12-28
IL283639B2 (en) 2024-06-01
JOP20210154A1 (ar) 2023-01-30
WO2020132648A1 (fr) 2020-06-25
CN113226473A (zh) 2021-08-06
TWI844602B (zh) 2024-06-11
US20220106293A1 (en) 2022-04-07
UY38526A (es) 2020-06-30
IL283639B1 (en) 2024-02-01
CO2021008224A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL291430A (en) mcl–1 inhibitors
IL269196A (en) New inhibitors
IL277006A (en) CD73 inhibitors
IL304348A (en) cd73 inhibitors
GB201705971D0 (en) Inhibitor compounds
ZA201907136B (en) Ip6k inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
IL276013A (en) pi4kiiibeta inhibitors
GB201819126D0 (en) Inhibitor compounds
GB201612860D0 (en) Inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL279419A (en) CCL5 inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201721465D0 (en) Inhibitors
GB201807845D0 (en) Kinase Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201809939D0 (en) Eastase inhibitor
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201819136D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds